Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Amardeep AwasthiDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States.ORCID 0000-0003-3237-9281
Anika PatelDepartment of Pharmacy Practice, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, 9401 Jeronimo Road, Irvine, California 92618, United States.
Huiying LiDepartments of Molecular Biology and Biochemistry, Pharmaceutical Sciences, and Chemistry, University of California, Irvine, California 92697-3900, United States.
Koon Mook KangDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States.ORCID 0000-0001-9336-840X
Christine D HardyDepartments of Molecular Biology and Biochemistry, Pharmaceutical Sciences, and Chemistry, University of California, Irvine, California 92697-3900, United States.ORCID 0000-0002-0780-025X
Anas AnsariDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States.ORCID 0000-0001-9069-8470
Raghad NowarDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States.
Md Emtiaz HasanDepartment of Pharmacy Practice, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, 9401 Jeronimo Road, Irvine, California 92618, United States.
Sun YangDepartment of Pharmacy Practice, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, 9401 Jeronimo Road, Irvine, California 92618, United States.
Thomas L PoulosDepartments of Molecular Biology and Biochemistry, Pharmaceutical Sciences, and Chemistry, University of California, Irvine, California 92697-3900, United States.ORCID 0000-0002-5648-3510
Richard B SilvermanDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States.ORCID 0000-0001-9034-1084
Funding
STRUCTURAL STUDIES ON NITRIC OXIDE SYNTHASER01GM057353 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI POULOS, THOMAS L · 1998 to 2018
$6.8M
Metalloenzyme structure, function, and as targets for neurodegeneration and bacterial pathogenesisR35GM131920 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI POULOS, THOMAS L · 2019 to 2023
$2.9M
Selective inhibition of nitric oxide synthase for multiple indicationsR35GM131788 · NIGMS · NORTHWESTERN UNIVERSITY · PI SILVERMAN, RICHARD B · 2019 to 2023
$2.3M
Development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for melanoma treatmentR01CA303584 · NCI · CHAPMAN UNIVERSITY · PI SUN YANG · 2025 to 2026
In 2024, an estimated 100,640 new cases of invasive melanoma were diagnosed in the U.S., with 9290 deaths. Our previous studies revealed that neuronal nitric oxide synthase (nNOS) derived nitric oxide plays a critical role in melanoma progression, making nNOS inhibition a promising strategy. High structural similarity among NOS isoforms requires careful design of nNOS inhibitors to avoid off-target effects. Our previous lead, HH044, demonstrated potent antimelanoma activity but exhibited only moderate nNOS selectivity. Here, we utilized a structure-based approach to design nNOS inhibitors that promote interactions with human nNOS-specific residue His342. Compound
Indexed as
Antineoplastic AgentsEnzyme InhibitorsMelanomaNitric Oxide Synthase Type IAnimalsCrystallography, X-RayHumansModels, MolecularRatsStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsNitric Oxide Synthase Type I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
New Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma. · full record | Socratic